iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

By WebmasterDecember 19, 2019November 1st, 2024No Comments

iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

Previous PostVenatorx Pharmaceuticals Joins the Alliance for Biosecurity
Next PostRelmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares